Baim Institute Names Dr. C. Michael Gibson As CEO
Pioneering Cardiologist Is Also Entrepreneur And Educator
BOSTON, Dec. 5, 2017 /PRNewswire/ -- The Baim Institute for Clinical Research, an influential non-profit medical research institute, today named C. Michael Gibson, M.S., M.D. as its President and Chief Executive Officer. Gibson is a cardiologist, researcher and educator. As one of the world's most cited cardiologists with over 500 manuscripts and book chapters, he is an internationally recognized thought leader in cardiovascular clinical trials and the regulatory process. Dr. Gibson is succeeding J. Spencer Goldsmith, who has decided to retire after over 15 years as President of the Institute. Mr. Goldsmith will continue at Baim for an additional period of time to facilitate the transition.
"We are delighted to have someone of Dr. Gibson's stature running the Institute," said Steven Freedman, Chairman of the Board of Trustees of the Institute. "His successes in the medical community, as well as his innovative entrepreneurial ventures give him the experience to take the Institute to the next level."
In addition to his clinical and research prominence, Dr. Gibson is perhaps best known for founding WikiDoc (www.wikidoc.org) an open source textbook of medicine which is the most widely viewed in the world. As WikiDoc's Editor-In-Chief, he oversees more than 2,200 active volunteer contributors to the world's largest, free and living medical textbook. WikiDoc is a non-profit charitable organization that does not receive industry support for its content. It has over 1,000 chapters that have been edited over 1.2 million times.
Dr. Gibson is also the founder of PERFUSE, an academic research organization that offers a full line of services for the management of clinical trials. Founded in 1987, PERFUSE provides protocol development, data entry and management, 6,000 trial sites worldwide, management of those sites and core laboratory services. For FDA submissions, regulatory meetings and global advisory panel hearings, PERFUSE provides scientific leadership and representation as well as full statistical services. PERFUSE is an international leader in the development of secure informational portals for clinical trials.
An interventional cardiologist, Gibson pioneered research on the "open artery" hypothesis, making it more easily understood. He also articulated the "microvasculature hypotheses" regarding heart attacks. This concept emphasizes the importance of restoring flow downstream in the capillary bed. Dr. Gibson has been selected for many years by U.S. News & World Report as one of America's top doctors.
"I am very much looking forward to leading the Baim Institute," said Gibson. "I see many synergies between the Institute and PERFUSE, and by working with the Board, I believe that we can enhance and expand the Institute's current contributions in the marketplace."
Dr. Gibson is an interventional cardiologist at the Beth Israel Deaconess Medical Center, a professor at the Harvard Medical School and a member of the FDA Cardiorenal Advisory Committee. He received his BS, MS and MD from the University of Chicago. Dr. Gibson will begin his new duties immediately.
About the Baim Institute: The Baim Institute for Clinical Research (formerly HCRI) is a leading non-profit academic research organization that delivers insight, innovation and leadership. The Institute collaborates with the world's most highly respected researchers from renowned institutions to design clinical trials. Their team is committed to finding creative solutions and delivering timely results that help advance health and quality of life around the world.
View original content with multimedia:http://www.prnewswire.com/news-releases/baim-institute-names-dr-c-michael-gibson-as-ceo-300566881.html
SOURCE The Baim Institute for Clinical ResearchBack to top